+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy



Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy



Therapeutic Advances in Medical Oncology 6(5): 222-228



Gastrointestinal stromal tumors (GISTs) are rare malignancies, and historically had a poor prognosis, with little benefit from traditional anticancer therapies. The management of GISTs has undergone a paradigm change in recent years with the detection of activating mutations in the majority of these tumors. This knowledge has led to the development of targeted treatments which have dramatically improved benefit rates and survival. The tyrosine kinase inhibitor, imatinib, has become the standard of care for both those with high-risk resected GIST, and as first-line therapy in metastatic GIST. However, some patients demonstrate innate resistance to imatinib or, for many, resistance develops despite an initial response. Other tyrosine kinase inhibitors with a broader spectrum of action, such as sunitinib and sorafenib, have been investigated and show some benefit after the use of imatinib. Regorafenib, an orally available multitargeted tyrosine kinase inhibitor with antiangiogenic activity, has also demonstrated preclinical evidence of activity against a number of solid tumors and further studies have proven it to be effective in GISTs following failure of standard therapy, with manageable toxicity profile. It has now received licensing approval in a number of countries both for the treatment of GISTs and for colorectal cancer, and further research is ongoing. With a number of potential agents now available to treat this disease, clinicians must now consider questions of timing and sequencing to maximize the benefit from these treatments, and the role that new agents such as regorafenib could play in further advancing changes.

(PDF emailed within 0-6 h: $19.90)

Accession: 055446609

Download citation: RISBibTeXText

PMID: 25342989

DOI: 10.1177/1758834014544892


Related references

Regorafenib in gastrointestinal stromal tumors. Future Oncology 10(9): 1581-1587, 2015

Regorafenib for treatment of advanced gastrointestinal stromal tumors. Expert Opinion on PharmacoTherapy 15(4): 549-558, 2014

Targeting gastrointestinal stromal tumors: the role of regorafenib. Oncotargets and Therapy 9: 3009-3016, 2016

The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Expert Opinion on Drug Safety 15(1): 105-116, 2016

The Cost-Effectiveness Of Regorafenib In The Treatment Of Metastatic/Inoperable Gastrointestinal Stromal Tumors In Turkey. Value in Health 18(7): A455-A455, 2015

Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Annals of PharmacoTherapy 47(12): 1685-1696, 2014

Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors. Indian Journal of Cancer 52(3): 257-260, 2016

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. International Journal of Clinical Oncology 20(5): 905-912, 2016

Estimation Of The Treshold Price Of Regorafenib In The Treatment Of Unresectable And/Or Metastatic Gastrointestinal Stromal Tumors After Failure On Imatinib And Sunitinib In Spain: Cost-Utility Analysis. Value in Health 18(7): A464-A464, 2015

Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report. Oncology Letters 11(1): 85-88, 2016

Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy. Zhonghua Wei Chang Wai Ke Za Zhi 17(4): 331-334, 2015

Gastrointestinal stromal tumors (GIST). Clinical characteristics, diagnosis, and therapy in five cases. Medizinische Klinik 101(1): 69-74, 2006

DNA copy number changes in gastrointestinal stromal tumors Evidence of an association with distal tumor site and distinct clinical behaviour. Pathology Research & Practice 199(4): 280, 2003

Clinical management of advanced gastrointestinal stromal tumors after failure of at least both imatinib and sunitinib targeted therapy. Zhonghua Wei Chang Wai Ke Za Zhi 18(4): 325-327, 2015

Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Annals of Diagnostic Pathology 11(1): 27-33, 2007